Skopos Labs, Inc. Neurocrine Biosciences Inc Transaction History
Skopos Labs, Inc.
- $813 Million
- Q3 2025
A detailed history of Skopos Labs, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Skopos Labs, Inc. holds 2,033 shares of NBIX stock, worth $294,500. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,033
Previous 2,945
30.97%
Holding current value
$294,500
Previous $413,000
30.99%
% of portfolio
0.04%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding NBIX
# of Institutions
724Shares Held
102MCall Options Held
230KPut Options Held
477K-
Black Rock Inc. New York, NY14.2MShares$2.06 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.41 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.56MShares$805 Million0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$685 Million0.04% of portfolio
-
State Street Corp Boston, MA4.35MShares$630 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...